simufilam

Cartoon of businessmen standing around a broken target
Biotech

Cassava stops Alzheimer's program as simufilam fails again

Months after seeing one phase 3 trial fail, the biotech plans to stop development altogether after chalking up another late-stage flop.
Nick Paul Taylor Mar 25, 2025 9:12am
A puzzle of the brain with one missing piece

Cassava claims win in open-label Alzheimer's study, shares fall

Jan 24, 2023 11:30am